Cervical Cancer Diagnostic Test Market Size, Share And Forecasts, 2018 To 2026
Posted by johnson on March 29th, 2019
The latest market report published by Credence Research, Inc. “Cervical Cancer Diagnostic Test Market - Growth, Future Prospects, and Competitive Analysis, 2018 - 2026” the cervical cancer diagnostic test market was valued at US$ 8,779.2 Mn in 2017 and expected to reach US$ xx Mn by 2026 at a CAGR of 8.6 % during the forecast period from 2018 to 2026.
Browse the full report Cervical Cancer Diagnostic Test Market Growth, Future Prospects, and Competitive Analysis, 2018 - 2026 at https://www.credenceresearch.com/report/cervical-cancer-diagnostic-test-market
An infection or abnormal cell growth on the surface of the cervix leads to cervical cancer, develop uncontrollably, and frame a tumor. Cervical cancer diagnostics test is the primary examination of the cancer patients, done through Pap (Papanicolaou) smear test and HPV (Human papillomavirus) testing, in the following stage colposcopy and biopsy performed additionally to affirm further testing procedure. After the analysis performed effectively the patients at that point experiences imaging tests to begin the review of growth. Pap tests deliver real-time analysis of current cell growth and specify whether abnormal cell growth or tumor expected to become more cancerous in the future. Superior screening with HPV testing and Pap smear testing has significantly condensed mortality rate from cervical cancer globally; such testing can prevent cancers through early detection of abnormal cell growth and improved health care management.
In 2014, as per the American Cancer Society, there were in excess of 12,000 new instances of cervical malignancy in the U.S. Furthermore; more than 4,000 deaths registered from cervical cancer. High prevalence of the disease worldwide, majorly from developing nations i.e. more than 80% is driving the market growth of cervical cancer diagnostics market. According to the World Health Organization, cervical cancer is mainly responsible for more than 300,000 deaths annually worldwide.
Development of cervical cancer diagnostic test market driven by growing female population worldwide and rising predominance rate of cervical disease, a high occurrence rate of HPV (human papillomavirus) contaminations, a rising number of awareness programs for cervical malignancy, and government funding and initiatives for the early cure. Advanced products and innovations, and critical development in the HPV testing provide better opportunities in the worldwide market. In any case, changes in the regulations for cervical disease screening, and utilization of HPV antibodies are the key factors that are constraining the development of this market. Additionally, unverifiable reimbursement scenario is the key market challenge in this market. The other prominent growth factors include increasing diagnostic procedures worldwide with higher efficacy, increasing healthcare expenditure, better reimbursement coverage, and utilization of advanced diagnostic procedures in developing nations offers a potential advantage to the further growth of the market.
In any case, lack of early diagnosis and treatment, high financial investment and expensive medications, strict administrative rules, and reimbursement approach issues are the key components limiting the market growth during the forecast period. In addition, the worldwide monetary conditions in the healthcare sector in developing economies make a noteworthy open door for the extension of the market.
Key Market Movements:
By Diagnostic Test Type Segment
Like it? Share it!
About the Authorjohnson
Joined: February 23rd, 2017
Articles Posted: 806
More by this author